We are analyzing https://link.springer.com/article/10.1007/s00262-008-0570-x.

Title:
Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer | Cancer Immunology, Immunotherapy
Description:
Background The FOXP3 mRNA expression and the other regulatory T cell-related molecules were investigated and compared with clinicopathological parameters in human primary breast cancer. Method This study included 136 breast cancer patients operated in our department from 2003 to 2006. Total RNA was extracted from frozen normal breast and breast cancer tissues, and the expression of FOXP3, IL-10, TGFβ1 and CCL22 mRNA was evaluated using quantitative real-time RT-PCR. Result FOXP3, IL-10, TGFβ1 and CCL22 mRNA expressions were significantly higher in cancer tissue than in normal tissue, not only at pT1, 2, and 3 stages but also at the DCIS stage. There were positive correlations between FOXP3 and IL-10, FOXP3 and TGFβ1, as well as FOXP3 and CCL22 mRNA expressions, respectively. FOXP3 and IL-10 mRNA expressions were significantly upregulated in PgR-negative or HER2-positive tumors. Conclusion These results suggest that regulatory T cells are involved in tumor onset and progression in human primary breast cancer, possibly contributing to poor prognosis of patients with breast cancer.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

cancer, cells, breast, foxp, treg, article, tumor, expression, google, scholar, pubmed, mrna, patients, cas, regulatory, tgfβ, cell, tissue, ccl, expressions, status, progression, yamaguchi, tumors, normal, factor, cdcd, analysis, data, fig, sakaguchi, med, function, involvement, access, study, significantly, dcis, table, shown, immunol, liu, onset, primary, open, human, rna, tissues, quantitative, rtpcr,

Topics {✒️}

tumor-infiltrating cd4 + t-cell subpopulations quantitative real-time rt-pcr tumor-infiltrating foxp3+cd25+cd4+ regulatory article download pdf transforming growth factor-β vaccine-mediated antitumor immunity scarff–bloom–richardson grades 1 stimulated human cd4+cd25 agonistic anti-gitr mab rnase-free dnase set peripheral cd4+cd25-naïve tgf-beta1 cytokine expression tgf-beta signaling foxp3-expressing treg cells tgf-β signals naturally occurring cd4 cd4+cd25 high privacy choices/manage cookies t-cell receptor early-stage prostate tumors cancer-related imbalance treg cell migration cell-related molecules related subjects mammary gland development treg cell accumulation infiltrating breast carcinoma t-cell responses primary breast cancer anti-gitr antibodies [39] rnase-free water tissue-specific antigens [19] quantitative rt-pcr high-grade tumors anti-cd25 antibody inhibit intestinal inflammation naive cd4+cd25 full access anti-inflammatory mediators contaminating genomic dna foxp3+ tumor-infiltrating transcription factor foxp3 infiltrating ductal carcinoma treg cell development sentinel lymph nodes hormone receptor status cd4+cd25+ regulatory cd4+cd25 + regulatory cd4+cd25+ regulatory breast cancer tissues

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer
         description:The FOXP3 mRNA expression and the other regulatory T cell-related molecules were investigated and compared with clinicopathological parameters in human primary breast cancer. This study included 136 breast cancer patients operated in our department from 2003 to 2006. Total RNA was extracted from frozen normal breast and breast cancer tissues, and the expression of FOXP3, IL-10, TGFβ1 and CCL22 mRNA was evaluated using quantitative real-time RT-PCR. FOXP3, IL-10, TGFβ1 and CCL22 mRNA expressions were significantly higher in cancer tissue than in normal tissue, not only at pT1, 2, and 3 stages but also at the DCIS stage. There were positive correlations between FOXP3 and IL-10, FOXP3 and TGFβ1, as well as FOXP3 and CCL22 mRNA expressions, respectively. FOXP3 and IL-10 mRNA expressions were significantly upregulated in PgR-negative or HER2-positive tumors. These results suggest that regulatory T cells are involved in tumor onset and progression in human primary breast cancer, possibly contributing to poor prognosis of patients with breast cancer.
         datePublished:2008-08-07T00:00:00Z
         dateModified:2008-08-07T00:00:00Z
         pageStart:441
         pageEnd:447
         license:https://creativecommons.org/licenses/by-nc/2.0
         sameAs:https://doi.org/10.1007/s00262-008-0570-x
         keywords:
            FOXP3
            CCL22
            IL-10
            TGFβ1
            Regulatory T cells
            Oncology
            Immunology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0570-x/MediaObjects/262_2008_570_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0570-x/MediaObjects/262_2008_570_Fig2_HTML.gif
         isPartOf:
            name:Cancer Immunology, Immunotherapy
            issn:
               1432-0851
               0340-7004
            volumeNumber:58
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Masahiro Ohara
               affiliation:
                     name:Hiroshima University
                     address:
                        name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yoshiyuki Yamaguchi
               affiliation:
                     name:Hiroshima University
                     address:
                        name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
                        type:PostalAddress
                     type:Organization
                     name:Kawasaki Medical School
                     address:
                        name:Department of Clinical Oncology, Kawasaki Medical School, Kurashiki, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Kazuo Matsuura
               affiliation:
                     name:Hiroshima University
                     address:
                        name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shigeru Murakami
               affiliation:
                     name:Hiroshima University
                     address:
                        name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Koji Arihiro
               affiliation:
                     name:Hiroshima University
                     address:
                        name:Department of Anatomical Pathology, Hiroshima University, Hiroshima, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Morihito Okada
               affiliation:
                     name:Hiroshima University
                     address:
                        name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer
      description:The FOXP3 mRNA expression and the other regulatory T cell-related molecules were investigated and compared with clinicopathological parameters in human primary breast cancer. This study included 136 breast cancer patients operated in our department from 2003 to 2006. Total RNA was extracted from frozen normal breast and breast cancer tissues, and the expression of FOXP3, IL-10, TGFβ1 and CCL22 mRNA was evaluated using quantitative real-time RT-PCR. FOXP3, IL-10, TGFβ1 and CCL22 mRNA expressions were significantly higher in cancer tissue than in normal tissue, not only at pT1, 2, and 3 stages but also at the DCIS stage. There were positive correlations between FOXP3 and IL-10, FOXP3 and TGFβ1, as well as FOXP3 and CCL22 mRNA expressions, respectively. FOXP3 and IL-10 mRNA expressions were significantly upregulated in PgR-negative or HER2-positive tumors. These results suggest that regulatory T cells are involved in tumor onset and progression in human primary breast cancer, possibly contributing to poor prognosis of patients with breast cancer.
      datePublished:2008-08-07T00:00:00Z
      dateModified:2008-08-07T00:00:00Z
      pageStart:441
      pageEnd:447
      license:https://creativecommons.org/licenses/by-nc/2.0
      sameAs:https://doi.org/10.1007/s00262-008-0570-x
      keywords:
         FOXP3
         CCL22
         IL-10
         TGFβ1
         Regulatory T cells
         Oncology
         Immunology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0570-x/MediaObjects/262_2008_570_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00262-008-0570-x/MediaObjects/262_2008_570_Fig2_HTML.gif
      isPartOf:
         name:Cancer Immunology, Immunotherapy
         issn:
            1432-0851
            0340-7004
         volumeNumber:58
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Masahiro Ohara
            affiliation:
                  name:Hiroshima University
                  address:
                     name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yoshiyuki Yamaguchi
            affiliation:
                  name:Hiroshima University
                  address:
                     name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
                     type:PostalAddress
                  type:Organization
                  name:Kawasaki Medical School
                  address:
                     name:Department of Clinical Oncology, Kawasaki Medical School, Kurashiki, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Kazuo Matsuura
            affiliation:
                  name:Hiroshima University
                  address:
                     name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shigeru Murakami
            affiliation:
                  name:Hiroshima University
                  address:
                     name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Koji Arihiro
            affiliation:
                  name:Hiroshima University
                  address:
                     name:Department of Anatomical Pathology, Hiroshima University, Hiroshima, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Morihito Okada
            affiliation:
                  name:Hiroshima University
                  address:
                     name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Cancer Immunology, Immunotherapy
      issn:
         1432-0851
         0340-7004
      volumeNumber:58
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Hiroshima University
      address:
         name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
         type:PostalAddress
      name:Hiroshima University
      address:
         name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
         type:PostalAddress
      name:Kawasaki Medical School
      address:
         name:Department of Clinical Oncology, Kawasaki Medical School, Kurashiki, Japan
         type:PostalAddress
      name:Hiroshima University
      address:
         name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
         type:PostalAddress
      name:Hiroshima University
      address:
         name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
         type:PostalAddress
      name:Hiroshima University
      address:
         name:Department of Anatomical Pathology, Hiroshima University, Hiroshima, Japan
         type:PostalAddress
      name:Hiroshima University
      address:
         name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Masahiro Ohara
      affiliation:
            name:Hiroshima University
            address:
               name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
               type:PostalAddress
            type:Organization
      name:Yoshiyuki Yamaguchi
      affiliation:
            name:Hiroshima University
            address:
               name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
               type:PostalAddress
            type:Organization
            name:Kawasaki Medical School
            address:
               name:Department of Clinical Oncology, Kawasaki Medical School, Kurashiki, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Kazuo Matsuura
      affiliation:
            name:Hiroshima University
            address:
               name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
               type:PostalAddress
            type:Organization
      name:Shigeru Murakami
      affiliation:
            name:Hiroshima University
            address:
               name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
               type:PostalAddress
            type:Organization
      name:Koji Arihiro
      affiliation:
            name:Hiroshima University
            address:
               name:Department of Anatomical Pathology, Hiroshima University, Hiroshima, Japan
               type:PostalAddress
            type:Organization
      name:Morihito Okada
      affiliation:
            name:Hiroshima University
            address:
               name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
      name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
      name:Department of Clinical Oncology, Kawasaki Medical School, Kurashiki, Japan
      name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
      name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
      name:Department of Anatomical Pathology, Hiroshima University, Hiroshima, Japan
      name:Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

External Links {🔗}(142)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.4s.

LINK . SPRINGER . COM {}